| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2015 | 2014 | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3,6 Md € | +2.3% | 3,6 Md € | +36.0% | 2,6 Md € | -8.2% | 2,9 Md € | -13.4% | 3,3 Md € | -8.5% | 3,6 Md € | +23.6% | 2,9 Md € | +21.6% | 2,4 Md € | +28.8% | 1,9 Md € | +47.5% | 1,3 Md € | |
| EBITDA | 1,8 Md € | +2.6% | 1,8 Md € | +81.2% | 975,8 M € | -18.6% | 1,2 Md € | -25.8% | 1,6 Md € | -14.3% | 1,9 Md € | +39.8% | 1,3 Md € | +27.2% | 1,1 Md € | +52.6% | 695,1 M € | +24.5% | 558,4 M € | |
| Operating profit | 135,6 M € | +1579.2% | -9,2 M € | +98.8% | -751,6 M € | -5.5% | -712,3 M € | -20.6% | -590,6 M € | -186.0% | -206,5 M € | +62.4% | -548,8 M € | +33.5% | -824,9 M € | -32.7% | -621,5 M € | -149.5% | -249,1 M € | |
| Profit/loss | 113,8 M € | +1244.9% | 8,5 M € | +101.3% | -676,9 M € | -30.3% | -519,5 M € | -1.8% | -510,4 M € | -126.5% | -225,3 M € | +60.4% | -569,4 M € | +31.2% | -827,9 M € | -184.7% | -290,8 M € | -3116.8% | 9,6 M € | |
| Equity | 1,2 Md € | +6.6% | 1,1 Md € | +275.6% | 293,4 M € | -69.8% | 970,3 M € | +98.1% | 489,8 M € | -51.0% | 1,0 Md € | -18.4% | 1,2 Md € | -13.8% | 1,4 Md € | -48.8% | 2,8 Md € | -9.5% | 3,1 Md € | |
| Total assets | 7,2 Md € | +14.5% | 6,2 Md € | +21.6% | 5,1 Md € | -3.2% | 5,3 Md € | -17.3% | 6,4 Md € | -9.0% | 7,0 Md € | +5.9% | 6,7 Md € | -9.4% | 7,3 Md € | +39.8% | 5,3 Md € | -2.0% | 5,4 Md € | |
| Cash | 153,8 M € | +494.2% | 25,9 M € | -70.3% | 87,1 M € | -0.3% | 87,4 M € | -64.3% | 244,9 M € | -61.4% | 634,5 M € | -2.6% | 651,1 M € | +157.6% | 252,7 M € | +432.1% | 47,5 M € | -93.0% | 673,7 M € | |
| Debts | 5,6 Md € | +18.9% | 4,7 Md € | +7.7% | 4,3 Md € | +15.0% | 3,8 Md € | -28.5% | 5,3 Md € | -4.4% | 5,5 Md € | +7.6% | 5,1 Md € | -7.9% | 5,6 Md € | +143.5% | 2,3 Md € | +5.2% | 2,2 Md € | |
| Staff | 1 395,2 | 1 317,9 | 1 269,4 | 1 267,9 | 1 235,1 | 1 097,9 | 1 012,9 | 960 | 867 | 895,4 | ||||||||||
Private limited company · Anderlecht · incorporated on 24/12/2013 · 1 395,2 ETP
Private limited company profitable and well capitalised. Cash position rising (+494.2%).
Solid counterparty for a standard engagement.
UCB BIOPHARMA is a Private limited company incorporated in 2013. Its main activity is: Manufacture of pharmaceutical preparations. Its registered office is in Anderlecht. It employs on average 1 395,2 ETP workers (FTE).
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.
Source: Belgian Official Gazette